Join
Live feed
·
PRReleasevia Quantisnow
Alumis Inc. logo

Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus

ByQuantisnow·Wall Street's wire, on your screen.
ALMS· Alumis Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALMS (Alumis Inc.) and more on Quantisnow.